The Symplicity Spyral™ renal denervation system, which is used during the Symplicity™ procedure, is backed by multiple sham-controlled trials and the largest real-world registry. The SPYRAL HTN clinical program is the largest renal denervation clinical program, studying more than 4,000 patients worldwide.†,‡,1–3 Read on to understand our extensive clinical evidence and sign up for email to receive the latest resources.
The Symplicity Spyral™ system is proven to deliver significant, safe, and sustained blood pressure reductions.1–5
Significant
> 9 mmHg
mean reduction in office systolic blood pressure (SBP) in patients on and off medications at primary endpoint follow-up in multiple clinical trials1,2
Safe
< 0.4%
major adverse events at composite endpoint, including no new incidence of renal artery stenosis (> 70%) at 6 months.2
(N = 253)
Sustained
17 mmHg
mean reduction in office SBP real-world patients at three years with the Symplicity™ renal denervation catheter.†,4
(N = 1,337)
Results may vary.
Individual trial designs vary.
Results may vary.
In the absence of medications
In the presence of medications
Read on to learn more about the SPYRAL HTN clinical program, including:
Now enrolling the post-approval study at sites across the United States.
Learn more about the turning point in hypertension care and how it can help enhance treatment strategies.
Learn about Symplicity Spyral™ RDN system’s components and their role in the Symplicity™ blood pressure procedure.
Sign up for email so we can send relevant information and resources directly to your inbox.
† Includes Symplicity Spyral™ and Flex RDN catheters.
‡ Study follow-up is ongoing. Data does not represent follow-up for all patients.
